SMMT Stock Plunges Overnight On FDA Rejection — CAPR Holders Feel The Jitters Ahead Of Their Own FDA Test

Capricor (CAPR) reported positive results from its Hope-3 trial, showing Deramiocel slowed decline in arm and hand function. CEO Linda Marban expressed confidence ahead of the PDUFA date. Retail sentiment on Stocktwits was bullish for both CAPR and Summit Therapeutics (SMMT), despite SMMT's stock plunging 19% year-to-date and CAPR falling 67%.

Original reporting
Published Nov 16, 2026, 1:49 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 2:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SMMT Stock Plunges Overnight On FDA Rejection — CAPR Holders Feel The Jitters Ahead Of Their Own FDA Test — source image
Decision brief

The 30-second read

$CAPRBullishMed
01

Why it matters

The trial data provides fresh, material information that could influence CAPR's stock price ahead of the upcoming FDA decision.

02

Market read

Biotech investors focus on trial outcomes; this news may trigger short‑term price movement.

03

What to watch

Potential safety concerns or manufacturing scale‑up challenges not addressed in the release.

Relevance 8/10Novelty 8/10Timing: today

Background

The article discusses retail sentiment on StockTwits and reports Capricor's Phase 2 trial results for Deramiocel, a therapy for arm and hand function decline.

Company-level read

Ticker impact

$CAPRBullishHigh confidence
Context

Capricor reported Phase 2 trial data showing Deramiocel slowed functional decline versus placebo.

Expected impact

likely upward pressure as market prices in potential approval expectations

Evidence & confidence

Clinical data is a material catalyst; investors often bid up biotech stocks on favorable results.

Market effects

May lift sentiment for other gene‑therapy and rare‑disease biotech firms.

US biotech sector could see modest gains.

Limited to investors tracking FDA‑regulated therapeutics.

Counterpoint

Skeptics may wait for FDA decision before taking positions, citing past trial‑to‑approval attrition.

Key entities

  • Capricor Therapeutics

    Biotech firm developing Deramiocel.

Related articles

$NVDAMed

NVDA Earnings Spark Tech Rally As US Futures Climb — BABA, INTC, ASTS In Focus

Nvidia (NVDA) reported strong Q3 earnings, beating revenue and EPS estimates, driving early premarket gains. Alibaba (BABA) faces scrutiny over ties to a suspected Chinese spy. Intel (INTC) reportedly laid off employees as part of restructuring. Capricor Therapeutics (CAPR) awaits FDA decision on its DMD therapy. AST SpaceMobile (ASTS) faces investor concerns over rocket development. Klarna (KLAR) reported better-than-expected Q3 revenue but missed adjusted EPS estimates.

$NVDAMed

Futures Climb As Nvidia Earnings Boost AI Trade — BABA, INTC, ASTS, CAPR In Focus

Nvidia reported 103% revenue growth to $115.8B, beating estimates. U.S. stock futures rose early Wednesday. Alibaba faces scrutiny over ties to a suspected Chinese spy. Intel confirmed layoffs. Capricor awaits FDA decision on Deramiocel. AST SpaceMobile faces investor concerns over rocket development. Klarna reported Q3 revenue of $1.009B, narrowing losses. Target, Palo Alto Networks, Lowe's, and TJX are set to report earnings.

$SLSMed

‘Pharma Bro’ Shkreli Calls SLS Results ‘Sketch,’ Compares Leukemia Vaccine Data To Capricor’s Deramiocel

SELLAS Life Sciences (SLS) reported that its REGAL trial of the galinpepimut-S cancer vaccine met the primary overall survival endpoint, with median survival of 24 months vs. 14.7 months for the best available treatment. Shares jumped over 200% on the news. Former pharmaceutical executive Martin Shkreli criticized the data, comparing it to Capricor Therapeutics' (CAPR) Deramiocel data and predicting FDA rejection.